Doxorubicin-induced cardiotoxicity is related to its production of free radicals that specifically affect heart tissue because of its low antioxidant status. Monohydroxyethylrutoside (monoHER), a potent antioxidant flavonoid, is under development as a protector against doxorubicin-induced cardiotoxicity. The overexpression of high levels of superoxide dismutase (sod) protects against free radical damage in transgenic mice. Seeking alternatives besides the few cardioprotectors that are presently under investigation, the aim of the present study was to investigate the protective effect of cardiac gene transfer of CuZn-sod compared with that of the presently most promising cardioprotector monoHER against doxorubicin-induced cardiotoxic effects on neonatal rat cardiac myocytes (NeRCaMs) in vitro. NeRCaMs were infected with different multiplicity of infections (MOIs) of adenovirus encoding CuZn-sod (AdCuZn-sod). A control infection with an adenovirus vector encoding a nonrelated protein was included. The overexpression of CuZn-sod was characterized within 3 days postinfection.
T he optimal use of doxorubicin in the clinic is restricted by the development of cumulative dose-related cardiotoxicity. This cardiotoxicity was explained by the production of free radicals by redox cycling of doxorubicin. [1] [2] [3] In an effort to overcome this problem, the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) and ICRF-187 seemed promising in the protection against doxorubicin-induced cardiotoxicity in vitro and in vivo [4] [5] [6] without interfering with its antitumor activity. ICRF-187, however, showed transient leucopenia and moderate thrombocytopenia, 6 thus amplifying the myelotoxicity of doxorubicin. The cardioprotection of monoHER was attributed to its potent free radical scavenging and metal ion chelating properties 7, 8 and thus compensating for the low antioxidants content of the heart tissue. [9] [10] [11] [12] Alternatively, the antioxidant capacity of the heart tissue can be directly enhanced by increasing the level of antioxidant enzymes inherently present in the heart tissue of doxorubicin-treated animals. Among these enzymes comes superoxide dismutase (sod) as an essential player in the detoxification of free radicals. Sod converts superoxide anion radicals into hydrogen peroxide, which is subsequently converted into water and oxygen. 13 The importance of sod in the protection against doxorubicin-induced cardiotoxicity has been previously investigated. Sod is present in three forms, intracellular (sod1/CuZn-sod), which represents 85-90% of the total sod, mitochondrial (sod2/Mn-sod) and an extracellular form (sod3/CuZn-sod).
14 Reduction of the CuZn-sod level of cardiac myocytes increased its sensitivity to doxorubicin damage in vitro. 15 Others have also shown that the overexpression of high levels of Mn-sod protected transgenic mice against doxorubicin cardiotoxicity while lower levels did not. 16 The overexpression of Mn-sod has also been shown to partially protect against doxorubicin inhibition of the activity of the respiratory complex in transgenic mice. 17 Yet, no data have shown the protective effect of the overexpression of CuZn-sod against doxorubicin-induced cardiotoxicity.
The growing interest in gene therapy and its potential clinical applicability prompted us to study the cardioprotection obtained by cardiac gene transfer of CuZn-sod against doxorubicin-induced cardiotoxicity. As a result of of our knowledge about the cardioprotection of mono-HER, this compound was used as a reference cardioprotector in this study.
The aim of the present study was to investigate the protective effect of cardiac gene transfer of CuZn-sod compared with the protective effect of monoHER against the cytotoxic effects of doxorubicin on the survival, LDH release and the beating rate of neonatal rat cardiac myocytes (NeRCaMs) in vitro.
Materials and methods

Adenovirus vectors
CuZn-sod encoding adenovirus (AdCuZn-sod) 18 was kindly provided by Dr RG Crystal (Joan and Sanford I, Weill Medical College, Cornell University). The AdCuZn-sod contains the cDNA of human CuZn-sod driven by the human cytomegalovirus (CMV) immediate-early promoter. The vector was generated in the background of adenovirus Ad5dl309, which has a deletion in part of the E3 19 using the pJM17 system. 20 As a control for the adenoviral infection, cells were infected with an adenovirus encoding nonrelated protein. The recombinant adenovirus vectors were propagated in PER C6 cells, 21 purified by CsCl density gradient. The viral preparations were dialyzed and stored at -801C until use. The titer of each viral stock was determined on 911 cells. 22 The titers ranged between 4 and 5 Â 10 10 PFU/ml.
The adenovirus stocks were free of replication competent adenovirus (RCA) as tested by PCR using primers flanking the AdE1A region. 23 NeRCaMs isolation and culture The digestion mixture was incubated at 371C for 20 minutes with shaking in the presence of glass beads, which assist the release of free cells from the digested tissue. The digestion step was repeated for undissociated tissue and the cell suspension of the two digestion steps was pooled in one tube kept on ice. The cells were spun down by centrifugation at 240 g for 15 minutes. The cell pellet was suspended in preplating medium, containing Ham's F-10 (Life Technologies, Breda, The Netherlands), 10% fetal bovine serum (FBS, Life Technologies) and 10% horse serum (HS, Life Technologies), and preplated in a 10 cm Petri dish (Falcon Primaria, Becton-Dickinson, Etten-Leur, The Netherlands) at 371C. The fibroblasts were left to attach for 25 minutes.
The unattached neonatal rat cardiac myocytes (NeRCaMs) were collected by careful shaking of the plates. The myocyte cell suspension was divided over six-well or 24-well plates with a final cell density of 5 Â 10 4 cell/cm 2 . NeRCaMs were left to attach for 5-7 hours. Thereafter, the preplating medium was refreshed with culture medium consisting of equal portions of Dulbecco's modified Eagle's medium (DMEM, Life Technologies) and Ham's F-10 and containing 100 U/ml penicillin, 100 mg/ml streptomycin and 5% HS. Cells were incubated at 371C in humidified air containing 5% CO 2 . These cultures contained at least 90% of synchronously beating NeRCaMs. The medium was refreshed after 24 hours. At 48 hours thereafter NeRCaMs cultures were ready for use.
In vitro gene transfer and sod activity and content determination
NeRCaMs cultured in six-well plates were incubated with different MOIs (25, 50 and 75) of AdCuZn-sod in growth medium (1 ml/well) at 371C. At 1 hour postinfection, another volume of virus-free growth medium was added. Control cells were infected with adenovirus encoding unrelated protein (MOI 75).
The cells were lysed 24, 48 and 72 hours postinfection with Ripa buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate (DOC, Fluka Biochem-ika, Buchs, Switzerland) and 1% Nonidet P40 (NP40, Fluka Biochemika)). The cellular lysates were immediately placed on ice for total sod activity determination and the remaining lysates were kept at À801C for Western blot analysis.
The total sod activity was measured by the cytochrome c reduction inhibition assay. 25 In brief, 25 ml of (properly diluted) cellular lysate was mixed with 25 ml of (0.11 U/ml) xanthine oxidase (Sigma Aldrich Chemie, Zwijndrecht, The Netherlands) solution in 1.5 ml of phosphate buffer (pH 7.8) containing 50 mM xanthine (Sigma Aldrich Chemie) and 10 mM ferricytochrome c (Sigma Aldrich Chemie). The rate of ferricytochrome c (DA/min) reduction was followed spectrophotometrically at a wavelength of 550 nm. A set of calibration samples was freshly prepared and measured at the day of analysis. The total sod activity in the cellular lysates was calculated by interpolating the DA/min of each test sample on the calibration line obtained by plotting the DA/min against the sod concentration of the calibration samples.
For the specific determination of CuZn-sod content, 50 mg protein of each sample (determined by Biorad total protein assay (Bio-Rad Laboratories B.V., Veenendaal, The Netherlands)) was separated on a 12.5% SDS-PAGE. Thereafter, the proteins were blotted on Immobilon membrane (Millipore B.V., Etten-Leur, The Netherlands). The membrane was rinsed in blocking solution containing 5% nonfat milk, 0.2% Tween 20, 150 mM NaCl and 10 mM Tris-Cl, pH 8. Subsequently, CuZn-sod protein was immunoprobed with sheep anti-human CuZn-sod 1 ry antibody (1:500 dilution) (The Binding Site, Birmingham, UK). The blot was incubated with peroxidase-conjugated donkey anti-sheep IgG 2 ry antibody (Jackson Immuno Research Laboratories Incorporation, West Grove) (1:1000 dilution). For the chemiluminescence detection, the blot was immersed in 0.025% luminol solution containing 0.01% H 2 O 2 and exposed to hyperfilm (Kodak).
MTT assay and LDH release
The cells grown in 24-well plates were divided into three groups (Fig 1a) . In one group, the cells were infected with AdCuZn-sod. At 3 days postinfection, the cells were treated with different concentrations of doxorubicin (0-50 mM). In parallel, the other two groups of noninfected NeRCaMs were treated with doxorubicin (0-50 mM) alone or with 1 mM monoHER (solubilized with 0.5% DMSO). DMSO (0.5%) did not show any effect on the viability or LDH release from treated cells compared to the blank. At 24 and 48 hours after doxorubicin treatment, the medium was collected for LDH measurement and the cells were washed with phosphate-buffered saline for the MTT assay.
The LDH activity was measured 26 by mixing 10 ml of the medium with 10 ml of 50 mM sodium pyruvate (Merck, Amsterdam, The Netherlands) solution in 1 ml TEA buffer (containing 500 mM triethanolamine, 100 mM MgCl 2 , 50 mM EDTA and 0.2 mM NADH, (Sigma Aldrich Chemie, Zwijndrecht, The Netherlands)).
The rate of NADH oxidation was followed at a wavelength of 340 nm. The percentage LDH release in the medium was plotted against the doxorubicin concentration (taking the blank as zero percent release).
The MTT assay was performed according to Mosmann 27 with minor modifications. The percentage survival (taking the blank as 100% survival) was plotted as a function of doxorubicin concentration.
Beating rate measurement
Three groups of cells were assigned for the beating rate measurement (Fig 1b) . The first group was infected with AdCuZn-sod followed by doxorubicin treatment (0-100 mM) 3 days postinfection. The other groups were treated with different concentrations of doxorubicin (0-100 mM) with or without 1 mM monoHER (solubilized with 0.5% DMSO). DMSO (0.5%) alone did not affect the beating rate of treated cells compared to the blank. The mean beating rate of treated cells was manually counted in two fixed spots/well within 72 hours after doxorubicin treatment. During counting, the CO 2 atmosphere and temperature around the cells were kept comparable to that in the incubator by sealing the plates with parafilm and placing them on a transparent thermostated box (391C) placed over the microscopic stage. The temperature in the medium was about 341C. Under these conditions, the beating rate was stable for at least 30 minutes.
In order to validate the manual counts, the beating of the cells was recorded on sVHS tapes through a phase 
Statistical analysis
The increase in the total sod activity in NeRCaMs infected with AdCuZn-sod (different MOIs) was statistically evaluated by ANOVA for the multiple regression of sod activity on AdCuZn-sod MOI and days after infection. In addition, Student's t-test was used to evaluate the activity of sod in cells infected with different MOIs of AdCuZn-sod compared with the blank or the control infection at the respective day. The change in the LDH release or survival of NeRCaMs treated with different concentrations of doxorubicin alone, with 1 mM monoHER or with AdCuZn-sod infection was statistically evaluated by the ANOVA for the multiple regression of ln (viability or LDH release) on ln doxorubicin concentration alone, with 1 mM monoHER or with AdCuZn-sod (MOI 25) infection. For the beating rate, the change was evaluated by the ANOVA for the multiple regression of ln % beating rate on ln time for each concentration of doxorubicin alone, with monoHER or with AdCuZnsod preinfection.
Results
Sod activity and content
The activity and content of sod in NeRCaMs infected with different MOIs (25, 50 and 75) of AdCuZn-sod are shown in Figure 2 . The total sod activity in control-virus infected cells did not significantly differ compared to untreated cells (blank, Po.2) up to 72 hours postinfection. Sod activity significantly increased at the third day of AdCuZn-sod infection (with different MOIs) compared to the blank (Po.029) and to the control (Po.038). No significant difference was observed between total sod activity in cells infected with the lower (MOI 25) and the higher MOIs (MOI 75) of AdCuZn-sod. CPEs have been observed at the third day after infection with an MOI of X50.
The Western blot (Fig 2) specifically shows a considerable MOI-and time-dependent increase in the level of hCuZn-sod in cells infected at different MOIs of AdCuZn-sod within 3 days postinfection.
Survival and LDH release
The survival of NeRCaMs and the LDH release 24 and 48 hours after treatment with different concentrations of doxorubicin with(out) preinfection with AdCuZn-sod (MOI 25) or cotreatment with 1 mM monoHER (MH) are shown in Figures 3 and 4 . The percentage of surviving NeRCaMs decreased in a concentration-dependent manner within 48 hours after doxorubicin treatment (Po.0005). The decrease in cellular viability was accompanied by a significant increase in the LDH release in the medium of doxorubicin-treated cells (Po.0005).
Infection with AdCuZn-sod (MOI 25) did not affect the viability of control NeRCaMs and no increase in the The P values (* compared to blank Po.029 and # compared to the control Po.038), which indicate significant increase in the total sod activity, were calculated by Student's t-test.
LDH release was observed during 5 days after infection.
A five-fold increase in the level of AdCuZn-sod did not protect against doxorubicin-induced decrease in the survival of NeRCaMs or the associated increase in the LDH release from the myocytes within 48 hours after doxorubicin treatment.
MonoHER per se did not influence the viability of NeRCaMs and no increase in the LDH release has been observed during 48 hours after treatment with 1 mM monoHER alone. The addition of 1 mM monoHER to doxorubicin ameliorated the damaging effects of doxorubicin. MonoHER significantly protected against the lethal effect of doxorubicin on the survival of NeRCaMs during 48 hours after doxorubicin treatment (Po.0005). MonoHER also significantly decreased doxorubicininduced LDH release from NeRCaMs 48 after doxorubicin treatment (P ¼ .004).
Beating rate
The effect of different concentrations of doxorubicin with or without preinfection with AdCuZn-sod (MOI 25) or cotreatment with 1 mM monoHER on the beating rate of NeRCaMs during 3 days after doxorubicin treatment is shown in Figure 5 . The beating rate of untreated cells (blank) was 109723 bpm and was relatively stable during the course of the experiment. Infection with AdCuZn-sod (MOI 25) or treatment with 1 mM monoHER alone did not significantly influence the beating rate of NeRCaMs compared to the blank. Doxorubicin significantly decreased the beating rate of NeRCaMs in concentration-and time-dependent manner (Po.0005). The time at which cells stopped beating (t zero ) is summarized in Table 1 . The t zero was inversely proportional to the doxorubicin concentration and ranged from 72 to 9 hours after treatment with 10 and 100 mM doxorubicin, respectively.
Infection with AdCuZn-sod (MOI 25) did not protect against the effect of doxorubicin on the beating rate of NeRCaMs during 72 hours after doxorubicin treatment (Table 1, Fig 5) , whereas the cotreatment with 1 mM monoHER significantly protected against doxorubicininduced reduction of the beating rate of NeRCaMs (Po.0005). MonoHER prolonged the t zero for 472 hours even in the presence of high concentrations (50, 100 mM) of doxorubicin (Table 1, Fig 5) .
Discussion
Sod is a key enzyme in the elimination of superoxide anion radicals by converting it into hydrogen peroxide, which is consequently removed by other antioxidant enzymes.
14 Free radical production is considered the main reason for doxorubicin toxicity to the heart tissue, which has a low antioxidant status. 9 The modulation of sod levels has been shown to greatly influence the sensitivity of the heart tissue to doxorubicin-induced toxicity. In early trials, exogenous sod was investigated as a protector against doxorubicin-induced cardiotoxicity. 28, 29 As a result of the limited penetration of sod into the cells variable protective effects have been observed. 30, 31 Indeed, when Mn-sod was endogenously expressed in high levels in transgenic mice a partial protection against doxorubicin-induced cardiotoxicity could be achieved. 16, 17 This incomplete protection might be the result of the confinement of Mn-sod to the mitochondria or of the possibility that the levels of Mnsod are still insufficient to show the desired cardioprotection. CuZn-sod that represents 80-90% of the total sod is located in the cytoplasm and may be considered as a first line of defense against doxorubicin damage, which makes it a good candidate for the protection against doxorubicin-induced cardiotoxicity. This was supported by the observation that reducing the level of CuZn-sod sensitizes cardiac myocytes to doxorubicin damage in vitro. 15 No studies have investigated the protective effect of CuZnsod in transgenic mice. Others, however, studied the protection of CuZn-sod against hypoxia-reoxygenation damage, which is also free radical mediated. 14, 18, 32, 33 In the present experiment, significant levels of CuZnsod were produced in NeRCaMs at the third day of infection with AdCuZn-sod compared to noninfected cells. However, the occurrence of cellular cytotoxicity limited the MOI of AdCuZn-sod to 25 PFU/cell. This titer was enough to produce a considerable increase (fivefold) in the activity of sod in infected cells at the third day of infection compared to blank. Others who used the same viral vector obtained comparable results using cytochrome c inhibition or auto-oxidation of pyrogalol assay for the determination of sod activity in infected cells. CuZn-sod activity increased two and eight folds in A549 cells infected with an MOI of 20 and 50 of AdCuZn-sod at the third day postinfection, respectively. 18 Others showed a 2-3-fold increase in the activity of CuZn-sod in islets 33 and aortic endothelial cells 34 3 days postinfection.
Doxorubicin alone decreased the viability of NeRCaMs in a concentration-dependent manner. This decrease was accompanied by an increase in the LDH release from treated cells. This is in line with previous reports, which showed that the free radicals produced by doxorubicin Sod gene transfer and doxorubicin-induced cardiotoxicity MAI Abou EI Hassan et al interact with the phospholipids of the cell membrane and produce membrane damage. 35 It is remarkable that when all the cells completely stopped beating, a fair fraction (10-16%) was still viable. This indicates that high-energy demanding processes like beating stop before the complete death of cells. This is probably a result of doxorubicin-induced reduction of the cellular ATP levels. 36 Five-fold increase in the level of CuZn-sod did not protect against doxorubicin cytotoxicity. The absence of protection can be attributed to the presence of insufficient levels of CuZn-sod that cannot counteract the free radicals produced by doxorubicin. Previous experiments, showed that only high level of Mn-sod protected against LDH and CK increase in the serum of transgenic mice. 16 Also complete protection was only obtained with a 10-fold increase in CuZn-sod in transgenic mice 32 while less than five-fold increase in sod activity did not fully protect against free radicals produced by doxorubicin 17 or hypoxia/reoxygenation. 14 MonoHER is a semisynthetic flavonoid. Flavonoids are a class of naturally occurring compounds, being ubiquitous in photosynthesizing cells, commonly used in traditional medicine. Recently, the beneficial effects of flavonoids have been raised in the treatment of different diseases. 37 In contrast with sod, monoHER significantly protected against doxorubicin cytotoxic effects (survival, LDH release and beating rate). The protection of monoHER was more pronounced mainly because of its wide range of properties. Firstly, monoHER has potent antioxidant properties 7, 8 that prevent free radical damage, produced by doxorubicin, via compensation for the low antioxidant content of the heart tissue. 9 Secondly, the metal ion chelating capacity of monoHER stops radical production by preventing iron cations from participating in redox cycling of doxorubicin and the subsequent production of more radicals. 7, 8 Finally, monoHER is also a good candidate for membrane protection as being one of the constituents of the flavonoid mixture Venorotun s , which is used in the treatment of chronic venous insufficiency presumably via the stabilization of collagen. 37 The combination of these properties makes monoHER a powerful protector against doxorubicin-induced cardiotoxicity. 4 In conclusion, the present study shows that a five-fold increase in the level of CuZn-sod was not enough to protect against doxorubicin-induced cardiotoxicity in cultured NeRCaMs. In contrast, monoHER protected NeRCaMs against doxorubicin-induced membrane damage (as illustrated by the increase in the LDH release from treated cells) and decrease in viability of treated cells. MonoHER also protected against the inhibiting effect of doxorubicin on the beating rate of cardiac myocytes, which is in agreement with the protecting effects of monoHER described earlier. 4, 5 MonoHER, 7-monohydroxyethylrutoside; sod, superoxide dismutase; NeRCaMs, neonatal rat cardiac myocytes; AdCuZn-sod, adenovirus encoding human CuZn-sod; pfu, plaqueforming unit; MOI, multiplicity of infection; LDH, lactate dehydrogenase; mM, micromol; CPE, cytopathic effects; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
